Board

Fredrik Sjövall, Chairman

Born: 1980
Appointed: April 5, 2017.
Qualifications: M.Sc. Automation Engineering, Master’s Degree in Business Development. Independent of Ziccum and its senior management. Independent of major shareholders of Ziccum.
Experience: Fredrik has got +15y experience from management positions in the life science industry. He was previously the CEO of Inhalation Sciences AB, Hemcheck AB, Lipopeptide AB and PharmaSurgics AB. Fredrik is currently the Chairman of the board at the listed companies Lipidor and Monivent and also at Emollivet AB, Ectin research AB, and Axelero AB.
Current roles: Chairman of the Board at Monivent AB, Lipidor AB, Emollivet AB, Ectin research AB, and Axelero AB.
Ownership: 111 000 shares and 9 200 warrants

Kristian Kierkegaard

Born: 1982
Appointed: May 18, 2018.
Qualifications: MBA with a Master’s Degree in Finance. Independent of Ziccum and its senior management. Independent of major shareholders of Ziccum.
Experience: Kristian has been an equity analyst at Remium Fondkommission and has been running his own investment company, Kristian Kierkegaard Holding AB, since 2011.
Current roles: Chairman of Kristian Kierkegaard Holding AB, Board member of AGOF Investments AB
Ownership: 157 420 shares and 9 200 warrants

Mattias Münnich

Born: 1979
Appointed: 25 April 2018.
Qualifications: Bachelor in Business Administration, and Master’s Degree in Venture Creation from Chalmers. Independent of Ziccum and its senior management. Independent of major shareholders of Ziccum.
Experience: Serial entrepreneur with Product and Business Development experience from a range of pharmaceutical companies. Co-founder and first Chairman of Stayble Therapeutics AB (Listed on First North), Co-founder and Director of Business Development at PharmaSurgics in Sweden AB (now ProMore Pharma AB, listed on First North). Co-founder and board member, Alpha Therapy Solutions AB.
Current roles: Mattias divides his time between VP Business Development at Stayble Therapeutics AB and mentors at Chalmers Ventures AB.
Ownership: 25 000 shares and 9 200 warrants

Mikaela Bruhammar

Born: 1976
Appointed: 20 Maj 2019.
Qualifications: MSc Molecular Biology. Independent of Ziccum and its senior management. Independent of major shareholders of Ziccum.
Experience: Mikaela has 20 years of experience working at major global life-science companies. She has held several strategic commercial roles and senior management positions in the Nordic region, on global and HQ level. During 1999-2008, various commercial roles with MSD Sweden AB, 2008-2012 local marketing and strategic roles with AstraZeneca Sweden and Nordic-Baltic. From 2012 to 2015 she was the Global Head of Astra Zeneca’s Vaccine Franchise, from 2015-2019 Vice President of Nordic-Baltic Business Unit in Respiratory, Inflammation and Autoimmune disease (RIA). Since Aug 2019 Head of Nordic Region for Real World Evidence at IQVIA.
Ownership: 9 000 shares and 9 200 warrants

Andreas Pettersson Rohman

BORN: 1980.
APPOINTED: April 27 2021.
QUALIFICATIONS: MSc. and BSc. Industrial Engineering and Management, Chalmers University of Technology. MSc. Advanced Finance, School of Business, Economics and Law, Gothenburg University. BSc National Economics, School of Business, Economics and Law, Gothenburg University.
EXPERIENCE: Andreas has extensive experience from strategy development as well as supportive debt and equity financing. He currently serves as Senior Director and leading the Corporate Finance department at Northvolt and previously worked as an Investment Professional at EQT within the Private Equity business line and prior to that at Goldman Sachs International in London within the Investment Banking Division.
He has also served as Member of the Board at the BlueStep Bank.
CURRENT ROLES: Vice president corporate finance and investor relations Northvolt AB

OWNERSHIP: Currently no share and 9 200 warrants.